Journal
BIOLOGY-BASEL
Volume 10, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/biology10090938
Keywords
Alzheimer's disease; idebenone; A beta; ADAM17; NEP; 5xFAD
Categories
Funding
- KBRI basic research program through KBRI - Ministry of Science, ICT & Future Planning [21-BR-02-11, 21-BR-02-22, 21-BR-03-05]
- National Research Foundation of Korea [2019R1A2B5B01070108]
- National Research Foundation of Korea [2019R1A2B5B01070108] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The study found that idebenone can modulate the pathology of Alzheimer's disease in 5xFAD mice through various pathways, including reducing Aβ plaque numbers, increasing Aβ degradation enzyme and alpha-secretase levels, and suppressing tau kinase levels, suggesting its therapeutic potential for AD.
The coenzyme Q10 analogue idebenone is an FDA-approved antioxidant that can cross the blood-brain barrier (BBB). The effects of idebenone on the pathology of Alzheimer's disease (AD) and the underlying molecular mechanisms have not been comprehensively investigated. Here, we examined the impact of idebenone treatment on AD pathology in 5xFAD mice, a model of AD. Idebenone significantly downregulated A beta plaque number via multi-directional pathways in this model. Specifically, idebenone reduced the RAGE/caspase-3 signaling pathway and increased levels of the A beta degradation enzyme NEP and alpha-secretase ADAM17 in 5xFAD mice. Importantly, idebenone significantly suppressed tau kinase p-GSK3 beta(Y216) levels, thereby inhibiting tau hyperphosphorylation at Thr231 and total tau levels in 5xFAD mice. Taken together, the present study indicates that idebenone modulates amyloidopathy and tauopathy in 5xFAD mice, suggesting therapeutic potential for AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available